Equities Analysts Set Expectations for CLDX FY2025 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Research analysts at Leerink Partnrs cut their FY2025 EPS estimates for shares of Celldex Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical company will post earnings per share of ($3.26) for the year, down from their prior forecast of ($3.22). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ FY2026 earnings at ($4.45) EPS and FY2027 earnings at ($4.20) EPS.

Other equities analysts also recently issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Trading Down 2.9 %

Shares of NASDAQ:CLDX opened at $23.29 on Friday. Celldex Therapeutics has a 1 year low of $22.17 and a 1 year high of $53.18. The business has a fifty day simple moving average of $25.32 and a 200 day simple moving average of $30.67.

Institutional Trading of Celldex Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its position in shares of Celldex Therapeutics by 14.5% during the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after buying an additional 1,167,659 shares during the last quarter. Jennison Associates LLC raised its holdings in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after acquiring an additional 321,325 shares in the last quarter. Emerald Advisers LLC lifted its position in shares of Celldex Therapeutics by 129.9% in the 3rd quarter. Emerald Advisers LLC now owns 456,202 shares of the biopharmaceutical company’s stock worth $15,506,000 after acquiring an additional 257,773 shares during the period. Fisher Asset Management LLC grew its holdings in shares of Celldex Therapeutics by 210.6% during the 3rd quarter. Fisher Asset Management LLC now owns 374,352 shares of the biopharmaceutical company’s stock worth $12,724,000 after purchasing an additional 253,808 shares in the last quarter. Finally, Readystate Asset Management LP bought a new stake in shares of Celldex Therapeutics during the third quarter valued at approximately $6,102,000.

Insider Buying and Selling

In related news, CEO Anthony S. Marucci bought 11,500 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the transaction, the chief executive officer now owns 40,284 shares of the company’s stock, valued at $1,080,416.88. The trade was a 39.95 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.80% of the stock is owned by insiders.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.